ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
ScripWelsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in
ScripThe Tariffs Before Tariffs In the years after the pandemic, but before the US-initiated trade wars hung over markets, the term ‘drug tariffs’ had a different significance. In Europe, especially Franc
ScripDegron Therapeutics, a Chinese specialist in molecular glue degraders (MGD), is looking beyond technology-based, compound screening collaborations with multinational big pharmas. MGDs, an emerging dru